COST-EFFECTIVENESS ANALYSIS OF CEMIPLIMAB FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CARCINOMA IN SPAIN

被引：0
|
作者：
Sanchez-Marin, J. [1 ]
Leon, L. [2 ]
Sanchez-Hernandez, A. [3 ]
Uria, E. [1 ]
Nieves, D. [1 ]
机构：
[1] Pharmalex, Barcelona, Spain
[2] Complexo Hosp Univ Santiago Compostela SERGAS, Translat Med Oncol Oncomet, Hlth Res Inst Santiago IDIS, Santiago De Compostela, Spain
[3] Consorcio Hosp Prov Castellon, Castellon De La Plana, Spain
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE327
引用
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Li, Yan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
    Lu, Tingting
    Huang, Yufan
    Cai, Zhongjie
    Lin, Wangchun
    Chen, Xiaoxiao
    Chen, Ruijia
    Hu, Yingying
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden
    Criss, Steven D.
    Palazzo, Lauren
    Watson, Tina R.
    Paquette, Adelle M.
    Sigel, Keith
    Wisnivesky, Juan
    Kong, Chung Yin
    PLOS ONE, 2020, 15 (01):
  • [4] Cost-effectiveness of pemetrexed for previously treated advanced non-small cell lung cancer
    Pavlakis, N
    Mitchell, PL
    Slynes, G
    Aristides, M
    Davey, P
    Rajan, N
    Arora, B
    Liepa, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 549S - 549S
  • [5] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA
    Ciuleanu, T. E.
    Dediu, M.
    Minea, L. N.
    Baculea, S.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2010, 13 (03) : A38 - A38
  • [6] Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain
    Presa, Maria
    Vicente, David
    Calles, Antonio
    Salinas-Ortega, Laura
    Naik, Jaesh
    Garcia, Luis F.
    Soto, Javier
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 659 - 671
  • [7] Cost-effectiveness of smoking cessation in patients with non-small cell lung cancer
    Kunde, Katharina
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2023, 28 (04): : 150 - 151
  • [8] Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada
    Sloka, JS
    Hollett, PD
    Mathews, M
    MEDICAL SCIENCE MONITOR, 2004, 10 (05): : MT73 - MT80
  • [9] Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy
    Ghetti, Gianni
    D'Avella, Maria Claudia
    Pradelli, Lorenzo
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 121 - 133
  • [10] Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Papachristos, A.
    Masinde, S.
    Davis, J. D.
    Gullo, G.
    Rietschel, P.
    Paccaly, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S308 - S309
12345